May 1, 2014
Bookmark and Share  
 
                 
  HCV
»
»
»
»
»



Follow us on
Twitter

HCVAdvocate


Join us on Facebook
Hcvadvocate Hcsp

 

Alan Franciscus

 

Greetings:

Spring is here and the HCV Advocate is doing a bunch of house cleaning.  In the coming weeks and months we will be revamping parts of our website and also some of the services we provide—so please stay tuned. 

This month’s issue of the HCV Advocate newsletter contains the most current information about treatment, advocacy and other issues related to hepatitis C.  We hope you enjoy being informed by our team of advocates!

 

Sincerely,

Alan and the staff of HCV Advocate

---------------------------------------------------------------------------

Do you want to stay up to date on the latest news about hepatitis C? Visit our HCV Advocate Blog for information about hepatitis C from around the world. The pipeline is also included in our blog that provides up-to-date information about the latest clinical trials and links to more information about specific trials.

---------------------------------------------------------------------------

1. HCV Advocate Newsletter: May 2014

In This Issue:

  • NEJM and EASL 2014
    Alan Franciscus, Editor-in-Chief—In this article I review the journal articles about the Phase 3 studies of all oral combinations to treat hepatitis C that are being developed by AbbVie and Gilead. In addition, some important and interesting data from EASL will also be discussed.

  • Snapshots
    Lucinda K. Porter, RN—In this issue there is an overview and analysis of journal articles about sofosbuvir/ribavirin vs. sofosbuvir/simeprevir cost-effectiveness, Vietnam Veterans' risk factors, beverages and HCV disease progression and a brief recap of the Action Plan for the Prevention, Care & Treatment of Viral Hepatitis.

  • HEALTHWISE: Hepatitis C: Ways to Fight Back
    Lucinda K. Porter, RN
    —Lucinda delves into HCV advocacy and how people can get involved.

 

-----------------------------------

 

2. HBV Journal Review: May 1, 2014, Vol 11, no 5, by Christine Kukka

In this month's column Chris reviews the following studies that will help you understand the complexities of hepatitis B, including interferon and HBV treatment, Vitamin E, and even an article about a TOAD:

  • Adding Interferon to Ongoing Antiviral Treatment Is Highly Successful
  • Vitamin E Helps HBV-Infected Children Lose HBeAg, Reducing Liver Damage
  • Common Chinese Toad May Hold the Key to Preventing and Treating Liver Cancer
  • Even at Top Hospitals, Doctors Fail to Treat Hepatitis B Patients Properly
  • Study Finds Doctors More Likely to Treat Hepatitis B in Men Than Women
  • Study Confirms Doctors Frequently Fail to Screen and Vaccinate Those at Risk
  • Antiviral Treatment Dramatically Improves Liver Cancer Test Accuracy
  • $50 Cash Incentive Increases HBV Immunization 12-Fold
  • Hepatitis B and C Cause Ten-Times More Deaths Than HIV in Europe

 

-----------------------------------

3. HCV Advocate News & Pipeline Blog!
Be sure to check out the latest clinical trial postings (Updated April 16, 2014) at the HCV Advocate News & Pipeline Blog. Just click on the links to the Drug Companies below the banner to see which drugs are in trials right now, where the trials are, and how to register for one.

-----------------------------------

4. Need Help?!
Call 877-HELP-4-HEP line (877-435-7443). The helpline is open from 9:00am to 7:00pm Eastern Time.

———————————————


 

 

Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org

**Questions and Comments: Questions and/or comments can be directed to alanfranciscus@hcvadvocate.org

**To receive the eblast in your email inbox simply send an e-mail to: listserv@list.hcvadvocate.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.

 
  HBV
»
»
»

Follow us on Twitter
HBVAdvocate